Vaccinex Announces up to $16.5 Million in Equity Financing Agreements and Provides an Update on COVID-19 Impact on its Clinical Programs ROCHESTER, N.Y., March 31, 2020 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and...

Vaccinex Announces Award Notice from the Alzheimer’s Association 2020 Part the Cloud Program Pepinemab (VX15), an experimental Vaccinex drug previously shown to prevent reduced brain glucose transport in Huntington’s disease, will be tested for similar effects in Alzheimer’s disease ...

Vaccinex, Inc. to Host Key Opinion Leader Luncheon on Huntington’s Disease ROCHESTER, N.Y., Jan. 30, 2018 (GLOBE NEWSWIRE) -- Vaccinex, Inc., a privately-held clinical-stage biotechnology company engaged in the discovery and development of human therapeutic monoclonal...

Vaccinex, Inc. Announces Preliminary Data from the SIGNAL Clinical Trial (Investigational Drug VX15/2503 as a Potential Treatment for Huntington’s Disease) - Subjects were rapidly recruited and consistently retained and dosed - - No concerning safety signals were identified - – Imaging data from SIGNAL Cohort A indicate treatment effect on...

Vaccinex, Inc. Announces Continuation of the SIGNAL Clinical Trial ROCHESTER, N.Y., Sept. 09, 2016 (GLOBE NEWSWIRE) -- Vaccinex, Inc., a clinical-stage biotechnology company engaged in the discovery and development of therapeutic monoclonal antibodies to treat...